Juventas (合源生物) focuses on developing CAR-T and cell therapy medicines. The company is building a CAR-T drug R&D platform to support its therapeutic pipeline. Funds from the recent financing will support construction of that platform and the implementation of the CNCT19 clinical trial. Management says the capital will accelerate translation of CAR-T and other cell therapy research into clinical development. The announcement identifies the company by its Chinese name and English trade name Juventas. No operating metrics or prior financial details were disclosed in the article.

Total raised

$24M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2018